James Hickman,
Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering,
University of Central Florida; Chief Scientist, Hesperos
James J. Hickman is the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science, Biomedical Engineering, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the Bioengineering Department at Clemson University. Dr. Hickman has a Ph.D. from the Massachusetts Institute of Technology in Chemistry. For the past thirty years, he has been studying the interaction of biological species with modified surfaces, first in industry and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their integration with electronic devices and MEMS devices. He is interested in creating hybrid systems for biosensor and biological computation applications and the creation of functional in vitro systems for human body-on-a-chip applications. He has worked at NSF and DARPA in the area of biological computation. He is also the founder and current Chief Scientist of a biotechnology company, Hesperos, that is focusing on cell-based systems for drug discovery and toxicity. He has 166 publications and 20 book chapters, in addition to 34 issued patents out of 50 total patent applications. He was elected to the Board of Directors of the American Institute for Medical and Biological Engineering (AIMBE) for 2 consecutive terms, the premier society for Biomedical Engineering of which he is a Fellow. He is also a Fellow of the American Vacuum Society (AVS) and National Academy of Inventors (NAI) as well as BioFlorida’s Researcher of the Year (2022). Dr. Hickman along with Dr. Michael Shuler, won the Lush Prize, in the Science Category, which Supports Animal Free Testing in 2015.
Human-on-a-chip Systems For Use in Efficacy and Toxicological Investigations in Pre-clinical Drug Discovery Utilizing Stem Cell-derived Disease Models
Friday, 5 October 2018 at 11:30
Add to Calendar ▼2018-10-05 11:30:002018-10-05 12:30:00Europe/LondonHuman-on-a-chip Systems For Use in Efficacy and Toxicological Investigations in Pre-clinical Drug Discovery Utilizing Stem Cell-derived Disease ModelsStem Cells in Drug Discovery and Toxicity Screening 2018 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
The utilization of multi-organ human-on-a-chip or body-on-a-chip systems for toxicology and efficacy, which ultimately should lead to personalized medicine applications, is a topic that has received much attention recently for drug discovery and subsequent regulatory approval. The considerable attrition-rate of drug candidates at all stages of development to a significant extent arises from the poor predictive nature of preclinical models for efficacy and toxicity, especially the inability to translate efficacy between preclinical and clinical situations. Systems capable of directly measuring organ function, biomarker release, and most importantly the synergistic interactions between organs, especially the generation of liver metabolites would be ideal. Our human-on-a-chip systems utilize function based cell models that accurately capture and predict multi organ complexity in response to administered compound within correctly scaled and physiologically relevant platforms. Our group, in collaboration with Dr. Michael Shuler from Cornell University, has been constructing these systems with up to 6 organs and have demonstrated long-term (>28 days) evaluation of drugs and compounds, that have shown similar response to results seen from clinical data or reports in the literature. Application of these systems for stem cell derived disease models of ALS and Alzheimer’s will be presented. Cardiac and skeletal muscle mechanistic toxicity and PDPK modeling will also be addressed. Additionally, this talk will give results of six workshops held at NIH to explore what is needed for validation and qualification of these new systems.
Add to Calendar ▼2018-10-04 00:00:002018-10-05 00:00:00Europe/LondonStem Cells in Drug Discovery and Toxicity Screening 2018Stem Cells in Drug Discovery and Toxicity Screening 2018 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com